Advertisement
Feature Article

Eliminating hepatitis C: Part 1. Finding your patients with hepatitis C

BRIDGET DRAPER, CHLOE LAYTON, JOSEPH DOYLE, Jessica Howell, David Baker, MARK STOOVÉ, ALISA PEDRANA
OPEN ACCESS
4.    Australian Institute of Health and Welfare (AIHW). Cancer in Australia: in brief 2019. Cancer series no. 122. Cat no. CAN 126. Canberra: AIHW; 2019. Available online at: www.aihw.gov.au/reports/cancer/cancer-in-australia-2019-in-brief/contents/table-of-contents (accessed June 2019).
5.    Dore GJ. Population-level impact of DAA treatment programs [conference presentation]. Australasian Viral Hepatitis Elimination Conference 2018. Available online at: https://az659834.vo.msecnd.net/eventsairaueprod/production-ashm-public/6d397de113f142c48288ff37f0910484 (accessed June 2019).
6.    Richmond JA, Ellard J, Wallace J, et al. Achieving a hepatitis C cure: a qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia. Hepatol Med Policy 2018; 3: 8.
7.    WHO. Combating hepatitis B and C to reach elimination by 2030 (advocacy brief). Geneva: WHO; 2016. Available online at: www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en (accessed June 2019).
8.    Murphy K. Just 12 countries worldwide on track to eliminate hepatitis C infection by 2030, with United Kingdom, Italy and Spain among those joining the list. 16 June 2018. Lafayette, CO: CDA Foundation; 2018. Available online at: https://cdafound.org/just-12-countries-worldwide-on-track-to-eliminate-hepatitis-c-infection-by-2030-with-united-kingdom-italy-and-spain-among-those-joining-the-list (accessed June 2019).
9.    Scott N, Hainsworth SW, Sacks-Davis R, et al. Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access. J Virus Erad 2018; 4: 108-114.
10.    Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 161-176. 
11.    Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018. Available online at: https://kirby.unsw.edu.au/report/hiv-viral-hepatitis-and-sexually-transmissible-infections-australia-annual-surveillance (accessed June 2019).
 

Pages

Ms Draper is a Research Assistant in Disease Elimination, Burnet Institute, Melbourne; and a PhD Student in the School of Population Health and Preventive Medicine, Monash University, Melbourne. Ms Layton is an EC Nurse Co-ordinator in Disease Elimination, Burnet Institute. Dr Doyle is Deputy Program Director of Disease Elimination, Burnet Institute; Adjunct Senior Lecturer in the School of Population Health and Preventive Medicine, Monash University; and Consultant Infectious Diseases Physician in the Department of Infectious Diseases, Alfred Hospital, Melbourne. Dr Howell is a Consultant Gastroenterologist at St Vincent’s Hospital, Melbourne; Postdoctoral Research Fellow in Disease Elimination, Burnet Institute; and Department of Medicine, University of Melbourne. Dr Baker is a GP at East Sydney Doctors; and Senior Lecturer at the University of Notre Dame Australia, Sydney, NSW. Professor Stoové is Head of the Public Health Discipline at the Burnet Institute; and Adjunct Research Fellow at the School of Population Health and Preventive Medicine, Monash University. Dr Pedrana is Postdoctoral Research Fellow in Disease Elimination, Burnet Institute; and Adjunct Research Fellow in the School of Population Health and Preventive Medicine, Monash University, Melbourne, Vic.